ESG Insider

Tag Archive for Abbott Laboratories

Weekend roundup: Abbott Laboratories, DCNS & Thales, Portugal’s privatisation, Shell and ‘Livelihoods’

Abbott Laboratories has agreed to pay fines totalling $1.5 billion for improperly marketing its anti-seizure drug, Depakote.

The judgement includes a $700 million criminal fine and $800 of civil settlements with the federal government and states.

The U.S. attorney for the western district of Virginia claimed that Abbott’s senior executives carried out a strategy of systematically marketing Depakote for uses unapproved by the FDA from 1998 to at least 2006.